Evidence map›Paper›PMID 39981176›Full record

ArticleFrontiers in pharmacology2025

Preclinical pharmaco-toxicological screening of biomimetic melanin-like nanoparticles as a potential therapeutic strategy for cutaneous melanoma.

Iasmina Marcovici, Raul Chioibas, Istvan Zupko, Iulia Pinzaru, Alina Moaca, Adriana Ledeti, Lucian Barbu-Tudoran, Andreea Geamantan, Iasmina Predescu, Cristina Adriana Dehelean

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Phytochemical Characterization and Biological Assessment ofAntioxidants (Basel, Switzerland) · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Iasmina MarcoviciFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy from Timisoara, Timisoara, Romania.
Raul ChioibasFaculty of Medicine, "Victor Babes" University of Medicine and Pharmacy from Timisoara, Timisoara, Romania.
Istvan ZupkoFaculty of Pharmacy, University of Szeged, Szeged, Hungary.
Iulia PinzaruFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy from Timisoara, Timisoara, Romania.
Alina MoacaFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy from Timisoara, Timisoara, Romania.
Adriana LedetiFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy from Timisoara, Timisoara, Romania.
Lucian Barbu-TudoranElectron Microscopy Laboratory "Prof. C. Craciun", Faculty of Biology and Geology, "Babes-Bolyai" University, Cluj-Napoca, Romania.
Andreea GeamantanFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy from Timisoara, Timisoara, Romania.
Iasmina PredescuFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy from Timisoara, Timisoara, Romania.
Cristina Adriana DeheleanFaculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy from Timisoara, Timisoara, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Despite its rarity, cutaneous melanoma (CM) represents the deadliest skin cancer with a high mortality rate, an incidence on the rise, and limited therapeutic options at present. Melanin is a polymeric pigment naturally produced within melanocytes and CM cells that gained a noteworthy attention due to its pharmacological properties, and potential for the design of nanoplatforms with biomedical applications. Up to date, the utilization of melanin-like nanoparticles (MEL-NPs) in cancer treatment has been well-documented, although their efficacy in CM therapy remains scarcely investigated. The current study presents the preclinical evaluation of MEL-NPs as a potential nanomedicine for CM management. Methods: MEL-NPs were produced through the oxidative polymerization of dopamine and characterized via electron microscopy and UV-VIS spectroscopy. The antioxidant activity was determined by using the DPPH method. The cytotoxic, anti-migratory, anti-clonogenic, pro-oxidant and pro-apoptotic properties of MEL-NPs were investigated Results: The as-made MEL-NPs presented a spherical morphology, an average size of 85.61 nm, a broad UV-VIS absorption spectrum, and a strong antioxidant activity. After a 24 h treatment, MEL-NPs exerted a selective cytotoxicity in SH-4 and B164A5 CM cells compared to HEMa, HaCaT, and JB6 Cl 41-5a healthy skin cells, except for the concentration of 100 µg/mL, at which their viability declined under 70%. Additionally, MEL-NPs accumulated within the intracellular space of CM cells, forming a perinuclear coating, inhibited their motility and clonogenic potential, increased intracellular oxidative stress, targeted the epithelial-to-mesenchymal transition, and induced apoptosis by altering cell morphology, nuclear aspect, F-actin and tubulin distribution, and by modulating the expression of pro- and anti-apoptotic markers. Conclusion: MEL-NPs demonstrated promising anti-melanoma properties, showing a selective cytotoxicity, a strong anti-invasive effect and a pro-apoptotic activity in CM cells, while inhibiting CAM angiogenesis, these novel findings contributing to future research on the potential application of this nanoplatform in CM therapy.

Indexed as

angiogenesisapoptosiscell migrationcutaneous melanomacytotoxicityepithelial-to-mesenchymal transitionirritant potentialmelanin-like nanoparticles

Identifiers

PMID39981176
PMCPMC11839674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.